Bronchiectasis - A Pipeline Analysis Report by Technavio
LONDON--(BUSINESS WIRE)--May 14, 2018-- has announced their latest pipeline analysis report on the market. The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat bronchiectasis.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180514005744/en/
Technavio has published a new pipeline analysis report on the global bronchiectasis market, including a detailed study of the pipeline molecules. (Graphic: Business Wire)
This report presents a detailed analysis of the market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the growth of the market in the coming years.
Bronchiectasis - market overview
occurs due to an infection or other medical condition that damages the walls of the airways, making it difficult to clear mucus. Mucus is a vile substance that the airways create to help remove inhaled dust, bacteria, and other small particles. The developed mucus breeds bacteria, causing regular infections. Bronchiectasis refers to abnormal dilation of the bronchial tree and is observed in a variety of clinical settings.
According to a senior analyst at Technavio for , “Presently, bronchiectasis has no cure. However, with appropriate care, people can lead a good life. Bronchiectasis can be cylindrical, varicose, and cystic. Early, diagnosis and treatment of bronchiectasis can lead to better chances of preventing lung damage.”
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
This market research report segments the market based on therapies employed that includes monotherapy and unknown, RoA (inhalation, oral, and unspecified), therapeutic modalities (small molecules, bio molecules, and undefined), targets for drugs under development (neutrophil elastase, P. aeruginosa, phosphonositide 3-kinase, DNA topoisomerase II and IV, and undisclosed), MoA (neutrophil elastase inhibitors, P. aeruginosa inhibitors, neutrophil elastase neutralizers, phosphatidylinositol 3-kinase delta inhibitors, DNA topoisomerase II and IV inhibitors, and undisclosed) drugs under development (discovery, pre-clinical, phase I, phase I/II, phase II, phase III, and NDA), and recruitment status (recruiting, completed, and undisclosed). It provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.
is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at .
View source version on businesswire.com:https://www.businesswire.com/news/home/20180514005744/en/
CONTACT: Technavio Research
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
INDUSTRY KEYWORD: HEALTH INFECTIOUS DISEASES PHARMACEUTICAL OTHER HEALTH
SOURCE: Technavio Research
Copyright Business Wire 2018.
PUB: 05/14/2018 09:36 AM/DISC: 05/14/2018 09:36 AM